LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 49

Search options

  1. Article ; Online: Commentary on "Evaluation of Patients for Zika Virus Infection in a Travel Clinic in the Southeast United States, 2016".

    Guisado-Vasco, Pablo

    Southern medical journal

    2019  Volume 112, Issue 1, Page(s) 52–53

    MeSH term(s) Humans ; Southeastern United States ; Travel ; Zika Virus ; Zika Virus Infection
    Language English
    Publishing date 2019-01-04
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 185329-6
    ISSN 1541-8243 ; 0038-4348
    ISSN (online) 1541-8243
    ISSN 0038-4348
    DOI 10.14423/SMJ.0000000000000918
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.117: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 336: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Commentary on "Stress Ulcer Prophylaxis in Hospitalized Patients, Subsequent Use in Primary Care and Physicians' Opinions About Acid-Suppressive Therapy".

    Guisado-Vasco, Pablo

    Southern medical journal

    2016  Volume 109, Issue 3, Page(s) 165–166

    MeSH term(s) Attitude of Health Personnel ; Female ; Histamine Antagonists/therapeutic use ; Humans ; Male ; Physicians ; Primary Health Care/methods ; Proton Pump Inhibitors/therapeutic use ; Stomach Ulcer/prevention & control ; Stress, Psychological/complications
    Chemical Substances Histamine Antagonists ; Proton Pump Inhibitors
    Language English
    Publishing date 2016-03
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 185329-6
    ISSN 1541-8243 ; 0038-4348
    ISSN (online) 1541-8243
    ISSN 0038-4348
    DOI 10.14423/SMJ.0000000000000429
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.117: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 336: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Cyclosporine A and COVID19 - The COQUIMA cohort - Author's reply.

    Guisado-Vasco, Pablo / Carnevali-Ruiz, Daniel / Vasallo, Israel John Thuissard

    EClinicalMedicine

    2020  Volume 31, Page(s) 100682

    Language English
    Publishing date 2020-12-24
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2020.100682
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Flipped Inflammatory Time and the Role of Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: Optimizing Tocilizumab Against Coronavirus Disease 2019.

    Guisado-Vasco, Pablo / Aguarles Gorines, José / Carralón González, María M / Sotres Fernández, Gabriel / Carnevali Ruiz, Daniel

    The Journal of infectious diseases

    2022  Volume 226, Issue 1, Page(s) 1–5

    Abstract: Use of interleukin (IL-6) inhibitors has become one of the most complicated clinical issues in treating coronavirus disease 2019 (COVID-19). Recently, randomized open-label platform trials have found that IL-6 inhibitors have a beneficial effect on ... ...

    Abstract Use of interleukin (IL-6) inhibitors has become one of the most complicated clinical issues in treating coronavirus disease 2019 (COVID-19). Recently, randomized open-label platform trials have found that IL-6 inhibitors have a beneficial effect on mortality in severe COVID-19. However, several questions arise around their mechanism of action in this disease, as well as how, when, and at which dose they should be used. IL-6 has both proinflammatory and anti-inflammatory effects, which may modulate the course of COVID-19, whose immunopathogenesis is driven by the innate immune system, autoantibodies, and interferon. Given that patients with delayed seroconversion against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein would be at the highest risk of complications beyond the second week of disease, we propose that considering patient serostatus at admission could optimize the use of IL-6 inhibitors in COVID-19. We predict that the net treatment benefits could be higher in the subgroup of patients with delayed seroconversion as compared to those who seroconvert more rapidly after SARS-CoV-2 infection.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; COVID-19/drug therapy ; Humans ; Interleukin-6 ; Randomized Controlled Trials as Topic ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus
    Chemical Substances Antibodies, Monoclonal, Humanized ; Interleukin-6 ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2022-03-17
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiac090
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.50: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 445: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Comments on the value International Prognostic Score (IPS), stage IV and age over 45 years, for the outcome of advanced Hodgkin lymphoma in chemotherapy containing adriamycin. The experience of the Spanish Hodgkin Lymphoma Study Group.

    Guisado-Vasco, Pablo / Montalban, Carlos / García, Juan F

    British journal of haematology

    2017  Volume 178, Issue 2, Page(s) 336–338

    Language English
    Publishing date 2017-07
    Publishing country England
    Document type Letter
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.14127
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort.

    Calderón-Parra, Jorge / Guisado-Vasco, Pablo / Montejano-Sánchez, Rocío / Estrada, Vicente / Cuevas-Tascón, Guillermo / Aguareles, José / Arribas, José / Erro-Iribarren, Marta / Calvo-Salvador, Marina / Fernández-Cruz, Ana / Ramos-Martínez, Antonio / Muñez-Rubio, Elena

    Journal of clinical medicine

    2023  Volume 12, Issue 3

    Abstract: Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts.: Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 ... ...

    Abstract Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts.
    Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated with sotrovimab between October 2021 and December 2021.
    Results: We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) and hematological malignancy (37.5%). Seven patients (21.9%) had respiratory progression: 12.5% died and 9.4% required mechanical ventilation. Patients treated within the first 14 days of their symptoms had a lower progression rate: 12.0% vs. 57.1%,
    Conclusions: Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.
    Language English
    Publishing date 2023-01-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm12030864
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis.

    Varona, Jose F / Landete, Pedro / Paredes, Roger / Vates, Roberto / Torralba, Miguel / Guisado-Vasco, Pablo / Porras, Lourdes / Muñoz, Patricia / Gijon, Paloma / Ancochea, Julio / Saiz, Elena / Meira, Fernanda / Jimeno, Jose M / Lopez-Martin, Jose A / Estrada, Vicente

    Frontiers in cellular and infection microbiology

    2023  Volume 13, Page(s) 1097809

    Abstract: Introduction: The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. In this follow-up study (E-APLICOV), the incidence of post-COVID-19 morbidity was evaluated and any long-term ... ...

    Abstract Introduction: The APLICOV-PC study assessed the safety and preliminary efficacy of plitidepsin in hospitalized adult patients with COVID-19. In this follow-up study (E-APLICOV), the incidence of post-COVID-19 morbidity was evaluated and any long-term complications were characterized.
    Methods: Between January 18 and March 16, 2022, 34 of the 45 adult patients who received therapy with plitidepsin in the APLICOV-PC study were enrolled in E-APLICOV (median time from plitidepsin first dose to E-APLICOV enrollment, 16.8 months [range, 15.2-19.5 months]). All patients were functionally autonomous with regard to daily living (Barthel index: 100) and had normal physical examinations.
    Results: From the APLICOV-PC date of discharge to the date of the extension visit, neither Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5) grade 3-4 complications nor QT prolongation or significant electrocardiogram (EKG) abnormalities were reported. Five (14.7%) patients had another COVID-19 episode after initial discharge from APLICOV-PC, and in 2 patients (5.9%), previously unreported chest X-ray findings were documented. Spirometry and lung-diffusion tests were normal in 29 (85.3%) and 27 (79.4%) patients, respectively, and 3 patients needed additional oxygen supplementation after initial hospital discharge. None of these patients required subsequent hospital readmission for disease-related complications.
    Discussion: In conclusion, plitidepsin has demonstrated a favorable long-term safety profile in adult patients hospitalized for COVID-19. With the constraints of a low sample size and a lack of control, the rate of post-COVID-19 complications after treatment with plitidepsin is in the low range of published reports. (ClinicalTrials.gov Identifier: NCT05121740; https://clinicaltrials.gov/ct2/show/NCT05121740).
    MeSH term(s) Humans ; Adult ; COVID-19 ; Follow-Up Studies ; SARS-CoV-2 ; Hospitals ; Treatment Outcome
    Chemical Substances plitidepsin (Y76ID234HW)
    Language English
    Publishing date 2023-02-22
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2619676-1
    ISSN 2235-2988 ; 2235-2988
    ISSN (online) 2235-2988
    ISSN 2235-2988
    DOI 10.3389/fcimb.2023.1097809
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: COVID-19 and Metabolic Syndrome: NF-κB Activation. Crossroads.

    Guisado-Vasco, Pablo / Cano-Megías, Marta / Rodríguez-López, Margarita / de-Luna-Boquera, Iris Mercedes / Carnevali-Ruiz, Daniel

    Trends in endocrinology and metabolism: TEM

    2020  Volume 31, Issue 11, Page(s) 802–803

    MeSH term(s) COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/genetics ; Diabetes Complications/epidemiology ; Humans ; Inflammation/genetics ; Insulin Resistance ; Metabolic Syndrome/complications ; Metabolic Syndrome/genetics ; NF-kappa B/genetics ; Obesity/complications ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/genetics ; Signal Transduction
    Chemical Substances NF-kappa B
    Keywords covid19
    Language English
    Publishing date 2020-08-28
    Publishing country United States
    Document type Letter
    ZDB-ID 1042384-9
    ISSN 1879-3061 ; 1043-2760
    ISSN (online) 1879-3061
    ISSN 1043-2760
    DOI 10.1016/j.tem.2020.08.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2999: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19

    Jorge Calderón-Parra / Pablo Guisado-Vasco / Rocío Montejano-Sánchez / Vicente Estrada / Guillermo Cuevas-Tascón / José Aguareles / José Arribas / Marta Erro-Iribarren / Marina Calvo-Salvador / Ana Fernández-Cruz / Antonio Ramos-Martínez / Elena Muñez-Rubio

    Journal of Clinical Medicine, Vol 12, Iss 864, p

    A Retrospective Multicenter Cohort

    2023  Volume 864

    Abstract: Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated ...

    Abstract Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated with sotrovimab between October 2021 and December 2021. Results: We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) and hematological malignancy (37.5%). Seven patients (21.9%) had respiratory progression: 12.5% died and 9.4% required mechanical ventilation. Patients treated within the first 14 days of their symptoms had a lower progression rate: 12.0% vs. 57.1%, p = 0.029. No adverse event was attributed to sotrovimab. Conclusions: Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.
    Keywords COVID-19 ; monoclonal antibodies ; sotrovimab ; severe COVID-19 ; immunocompromised hosts ; Medicine ; R
    Subject code 616
    Language English
    Publishing date 2023-01-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article: COVID-19 and Metabolic Syndrome: NF-κB Activation. Crossroads

    Guisado-Vasco, Pablo / Cano-Megías, Marta / Rodríguez-López, Margarita / de-Luna-Boquera, Iris Mercedes / Carnevali-Ruiz, Daniel

    Trends Endocrinol Metab

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #733608
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top